The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Effective immediately, only two people are permitted at the bedside of patients during the day and one person overnight at ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...